cis-platinum ototoxicity in children.
Cis-platinum is an ototoxic antineoplastic drug. Evaluation of auditory thresholds in 33 children receiving cis-platinum shows that a threshold shift at 6 and 8 kHz is first measurable after a cumulative dose of 201 to 300 mg/m2. A 35- to 40-dB high-frequency threshold shift is evident after a cumulative cis-platinum dose of 301 to 400 mg/m2. Increasing cumulative doses of cis-platinum are associated with a greater degree of hearing loss. Receiver-operator characteristic curves were used to find a criterion value that effectively identified threshold shifts that were due to cis-platinum ototoxicity. A 15-dB or greater shift in the 6- and 8-kHz threshold average identifies a high true-positive (50%) and low false-positive (0%) rate of cis-platinum-induced hearing loss. Using this criterion, cis-platinum ototoxicity affected 77% of children who received cis-platinum (median cumulative dose 360 mg/m2).
Pasic
T R
TR
Department of Otolaryngology, Head and Neck Surgery, University of Washington School of Medicine, Seattle.
Dobie
R A
RA
D000367:Age Factors; D001309:Auditory Threshold; D002648:Child; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006311:Hearing Disorders / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D012372:ROC Curve
D002945:Cisplatin